Related Experiment Video

Updated: Mar 15, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients

S Harrach1, C Schmidt-Lauber2, T Pap1

  • 1Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany.

Blood Cancer Journal
|September 17, 2016
PubMed

Insights

Multidrug and toxin extrusion protein 1 (MATE1) is crucial for imatinib uptake in chronic myeloid leukemia (CML) treatment. Measuring MATE1 levels can predict imatinib response in CML patients.

Area of Science:

  • Pharmacology
  • Oncology
  • Molecular Biology

Background:

  • Imatinib is a key treatment for chronic myeloid leukemia (CML).
  • However, 25-30% of patients exhibit resistance or relapse due to insufficient imatinib uptake.
  • Organic cation transporter 1 (OCT1) has been implicated in imatinib transport, but its role remains debated.

Purpose of the Study:

  • To investigate the role of MATE1 and OCT1 in imatinib cellular uptake and efficacy.
  • To determine if transporter expression levels correlate with imatinib response in CML patients.

Main Methods:

  • In vitro assessment of imatinib transport by MATE1 and OCT1.
  • Analysis of MATE1 and OCT1 expression in bone marrow cells from CML patients with varying imatinib responses.

Main Results:

  • MATE1 demonstrated significantly higher affinity for imatinib transport compared to OCT1.
  • MATE1, not OCT1, was identified as the primary transporter mediating imatinib cellular uptake.
  • Reduced MATE1 expression was observed in imatinib-non-responding CML patients compared to responders.
  • OCT1 expression levels did not correlate with imatinib response.

Conclusions:

  • MATE1 plays a critical role in mediating imatinib cellular uptake and determining its therapeutic effectiveness in CML.
  • MATE1 expression levels, rather than OCT1, are indicative of imatinib treatment success.
  • Measuring MATE1 expression could serve as an early predictive biomarker for imatinib response in CML patients.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

891
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K